Abstract
Safety and Preliminary Efficacy Results from a Phase Ib/II Study of Cobimetinib As a Single Agent and in Combination with Venetoclax with or without Atezolizumab in Patients with Relapsed/Refractory Multiple Myeloma
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have